Consistent with findings in other cancer cell lines (Kryukov et al, 2016; Mavrakis et al, 2016), we observed that the PRMT5 inhibitor JNJ-64619178 (onametostat) effectively reduced MKL-1 cell viability at sub-nanomolar doses after 8 and 11 d of treatment. This evidence concerns the gene PRMT5 and cancer.